ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

By M. Crespo, F. Bosch, N. Villamor, B. Bellosillo, D. Colomer, M. Rozman, S. Marcé, A. López-Guillermo, E. Campo, E. Montserrat. New England Journal of Medicine, 2003

1,445 citations recorded by the source corpus.

Subfields: Computational Mechanics

View Paper: https://www.semanticscholar.org/paper/9d4a914b5a0adb2b9265e365634aa023b040404f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. F. Malavasi
2. R. Busch
3. T. Denzel
4. Sonja Häbe
5. D. Winkler
6. A. Funaro
7. E. Ferrero
8. A. Horenstein

Citations in the corpus

• Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. (2008, neutral): “Median age, y (range) 57 (17-86) — Younger than 60 y 186 (62) 140 (75) 60 to 69 y 73 (24) 56 (77) 70 y or older 41 (14) 21 (51) Male 211 (70) 154 (73) Female 89 (30) 63 (71) Median time from diagnosis, mo (range) 24 (0-155) — Rai stage 0 11 (4) 10 (91) Rai stages I to II 182 (61) 136 (75) Rai stages”
• TP53 mutation and survival in chronic lymphocytic leukemia. (2010, background): “Other prognostic factors in CLL include serum markers, IGHV mutational status, and ZAP70 expression.(4,5,7,28,29) Despite numerous markers, genotype-specific trials for subgroups of CLL have only recently been designed for patients with 17p deletion, reflecting the distinctly poor prognosis of this ”
• Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. (2008, background): “More recently, the cytoplasmic kinase ZAP-70 has been identified as a further independent negative prognostic marker (50).”
• In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. (2005, background): “Expression of ζ chain–associated protein 70 kDa (ZAP-70) mRNA or protein (11, 12) and the presence of CD38 on the leukemic cell surface also presage poor outcome (9, 13–16).”